Compounds > n-nitroso-tris-chloroethylurea
Page last updated: 2024-11-08

n-nitroso-tris-chloroethylurea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-nitroso-tris-chloroethylurea: induces dysplasia and premalignant lesions [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID198521
SCHEMBL ID3138606
MeSH IDM0574207

Synonyms (20)

Synonym
urea, 1-nitroso-1,3,3-tris(2-chloroethyl)-
3-nitroso-1,1,3-tris(chloroethyl)urea
1-nitroso-1,3,3-tris-(2-chloroethyl)urea
nitrosotris(chloroethyl)urea
brn 2275935
tris(2-chloroethyl)nitroso-urea
n-nitrosotris-(2-chloroethyl)urea 90%
n,n,n'-tris(2-chloroethyl)-n'-nitroso-urea
1,1,3-tris(2-chloroethyl)-3-nitrosourea
FT-0673002
69113-01-5
urea,n,n,n'-tris(2-chloroethyl)-n'-nitroso-
DTXSID00219175
SCHEMBL3138606
89774-74-3
n-nitrosotris-(2-chloroethyl)urea
AKOS030239946
n-nitroso-tris-chloroethylurea
n-nitrosotris-(2-chloroethyl)urea 90per cent
ethanimidamide,n-[(butylamino)carbonyl]-2,2,2-trichloro-n-hydroxy-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's0 (0.00)29.6817
2010's7 (70.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.97 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		3.8100N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
3,3'-diindolylmethane
3,3'-diindolylmethane: anti-inflammatory from edible cruciferous vegetables; a cytochrome P-450 antagonist		2.1110indolesantineoplastic agent;
P450 inhibitor
honokiol
[no description available]		2.110biphenyls
lignans
Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		2.110
bromochloroacetic acid
Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.. bromochloroacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by bromine while a second is replaced by chlorine. A low-melting (27.5-31.5degreeC), hygroscopic crystalline solid, it can be formed during the disinfection (by chlorination) of water that contains bromide ions and organic matter, so can occur in drinking water as a byproduct of the disinfection process.		2.31102-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		2.2510stilbene
pterostilbene
[no description available]		2.2510diether;
methoxybenzenes;
stilbenol		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Non-Small Cell Lung
[description not available]		02.3110
Carcinoma, Epidermoid
[description not available]		03.8100
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.5170
Cancer of Lung
[description not available]		03.790
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.3110
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		03.8100
Lung Neoplasms
Tumors or cancer of the LUNG.		03.790
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.5520
Experimental Neoplasms
[description not available]		02.2110
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		07.0810
Innate Inflammatory Response
[description not available]		02.1110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1110
Disease Exacerbation
[description not available]		02.1310
Condition, Preneoplastic
[description not available]		02.520
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		02.520
Neoplasms, Bronchial
[description not available]		02.0710
Invasiveness, Neoplasm
[description not available]		02.0710
Bronchial Neoplasms
Tumors or cancer of the BRONCHI.		02.0710
Adenocarcinoma, Alveolar
[description not available]		01.9710
Metaplasia
A condition in which there is a change of one adult cell type to another similar adult cell type.		01.9710
Adenocarcinoma, Bronchiolo-Alveolar
A carcinoma derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)		01.9710